Ibrutinib
Treatment for Chronic Lymphoid Leukemia
Typical Dosage: 420mg daily orally
Effectiveness
86%
Safety Score
42%
Clinical Trials
172
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
42
DangerousModerateSafe
Treatment Details
Dosage Range
420mg daily orally
Time to Effect
1-3 months
Treatment Duration
Until progression or unacceptable toxicity
Evidence Quality
HIGHConfidence Score
94%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$160,000
Monitoring:$5,000
Side Effect Mgmt:$5,000
Total Annual:$170,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$168,782/QALY
QALYs Gained
1.2
Outcome-Based Costs
Cost per Responder
$200,000
Cost per Remission
$1,133,333
Comparison vs Bendamustine + Rituximab
Cost Difference
+$110,000/year
More expensive
QALY Difference
+0.40 QALYs
Better outcomes
Dominance
No dominance
Ibrutinib Outcomes
for Chronic Lymphoid Leukemia
Efficacy Outcomes
Overall Effectiveness
+86%
Response Rate
+85%
Remission Rate
+15%
Common Side Effects
Diarrhea
+48%
Atrial Fibrillation
+16%
Hypertension
+14%
Bleeding
+12%
Arthralgia
+10%
Sources:
Active Clinical Trials
5 active trials recruiting for Ibrutinib in Chronic Lymphoid Leukemia
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT01500733ACTIVE NOT RECRUITINGPHASE2
86 participants
INTERVENTIONAL
Bethesda, United States
Started: Jan 5, 2012
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
NCT04608318ACTIVE NOT RECRUITINGPHASE3
897 participants
INTERVENTIONAL
Graz, Austria +180 more
Started: Mar 1, 2021
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
NCT02787369ACTIVE NOT RECRUITINGPHASE1
3 participants
INTERVENTIONAL
Boston, United States
Started: May 1, 2016
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT02537613ACTIVE NOT RECRUITINGPHASE1
54 participants
INTERVENTIONAL
Boston, United States +3 more
Started: Dec 1, 2015
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT03462719ACTIVE NOT RECRUITINGPHASE3
211 participants
INTERVENTIONAL
Louisville, United States +86 more
Started: Apr 17, 2018
Completed Clinical Trials
12 completed trials for Ibrutinib in Chronic Lymphoid Leukemia
Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia
NCT02388048COMPLETEDPHASE2
19 participants
INTERVENTIONAL
Roma, Italy +34 more
Started: Oct 1, 2015
A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
NCT02264574COMPLETEDPHASE3
229 participants
INTERVENTIONAL
La Jolla, United States +70 more
Started: Oct 6, 2014
A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT02801578COMPLETEDPHASE2, PHASE3
11 participants
INTERVENTIONAL
Houston, United States
Started: Jul 6, 2016
Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL
NCT02758665COMPLETEDPHASE2
41 participants
INTERVENTIONAL
Cologne, Germany +10 more
Started: Sep 1, 2016
A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting
NCT03720561COMPLETED
312 participants
OBSERVATIONAL
Ancona, Italy +38 more
Started: Oct 30, 2018
A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT02556892COMPLETEDPHASE1
8 participants
INTERVENTIONAL
Fukuoka, Japan +7 more
Started: Jul 3, 2015
Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia
NCT02827617COMPLETED
56 participants
OBSERVATIONAL
Aviano, Italy +12 more
Started: Jun 1, 2016
Safety of PCI-32765 in Chronic Lymphocytic Leukemia
NCT01105247COMPLETEDPHASE1, PHASE2
133 participants
INTERVENTIONAL
Stanford, United States +9 more
Started: May 1, 2010
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
NCT01292135COMPLETEDPHASE1
33 participants
INTERVENTIONAL
Boston, United States +5 more
Started: Feb 1, 2011
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
NCT00849654COMPLETEDPHASE1
66 participants
INTERVENTIONAL
Palo Alto, United States +8 more
Started: Feb 1, 2009
Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program
NCT02582320COMPLETED
264 participants
OBSERVATIONAL
Ascoli Piceno, Italy +46 more
Started: Mar 1, 2016
A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT02406742COMPLETEDPHASE1, PHASE2
47 participants
INTERVENTIONAL
La Jolla, United States +23 more
Started: Jul 27, 2015
Showing 20 of 173 total trials